| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.17.3.528 |
| P8608 | Fatcat ID | release_bczzfx7wsbewfj4x32oa7m2fue |
| P698 | PubMed publication ID | 9102172 |
| P2093 | author name string | Xu H | |
| Rogers C | |||
| Simon DI | |||
| Rao NK | |||
| Ortlepp S | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 528-535 | |
| P577 | publication date | 1997-03-01 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. | |
| P478 | volume | 17 |
| Q37316783 | A bumpy and winding but right path to domestic drug-eluting coronary stents |
| Q36286707 | A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits |
| Q33392128 | A putative role for platelet-derived PPARγ in vascular homeostasis demonstrated by anti-PPARγ induction of bleeding, thrombocytopenia and compensatory megakaryocytopoiesis |
| Q77959634 | A risk-benefit assessment of abciximab in angioplasty |
| Q33504164 | Abciximab. An updated review of its use in ischaemic heart disease |
| Q37221177 | Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model |
| Q37929839 | Anti-platelet therapy: glycoprotein IIb-IIIa antagonists |
| Q43573530 | Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting |
| Q34027525 | Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents |
| Q34930685 | Bench to bedside: pathophysiology of acute coronary syndromes and implications for therapy |
| Q28483889 | Cardiopulmonary bypass during cardiac surgery modulates systemic inflammation by affecting different steps of the leukocyte recruitment cascade |
| Q33943133 | Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes |
| Q77958677 | Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty |
| Q28166129 | Comparative Pharmacology of GP IIb/IIIa Antagonists |
| Q42831038 | Darwin and the survival of the fittest in modern interventional cardiology. |
| Q33781957 | Development of eptifibatide |
| Q44563411 | Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity |
| Q34814479 | Do neutrophils contribute to myocardial reperfusion injury? |
| Q24796695 | Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion |
| Q41765654 | Effect of abciximab on the levels of circulating microparticles in patients with acute myocardial infarction treated by primary angioplasty |
| Q33502054 | Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets |
| Q73156905 | Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction |
| Q73583534 | Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction |
| Q28165946 | Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting |
| Q74709449 | Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty |
| Q38384596 | Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial. |
| Q34003157 | Endothelial cell delivery for cardiovascular therapy |
| Q81214093 | Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention |
| Q42238584 | Evolving coronary stents coated with new bioactive agents |
| Q33502467 | Glycoprotein IIb/IIIa antagonists: potential induction and detection of drug-dependent antiplatelet antibodies |
| Q28193156 | Glycoprotein receptor inhibitors in the management of acute coronary syndromes |
| Q44916106 | Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. |
| Q74016518 | Increased adhesiveness of white blood cells in patients with unstable angina: additional evidence for an involvement of the immune-inflammatory system |
| Q74172108 | Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease |
| Q36025986 | Inflammation as a mechanism and therapeutic target for in-stent restenosis |
| Q36369005 | Integrin alpha(M)beta(2)-mediated cell migration to fibrinogen and its recognition peptides |
| Q34912684 | Integrin targeted therapeutics |
| Q37011736 | Integrin αIIbβ3: from discovery to efficacious therapeutic target |
| Q81311780 | Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke. A preliminary feasibility and safety study in a non-human primate model |
| Q36557600 | Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach? |
| Q37279917 | Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction. |
| Q34051300 | Ischemic complications after percutaneous transluminal coronary angioplasty |
| Q43756320 | Leukocyte/endothelium activation and interactions during femoral percutaneous transluminal angioplasty |
| Q56944701 | Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention |
| Q30305538 | Management of Acute Ischemic Coronary Syndromes: The Present and Future |
| Q51798983 | Material‐induced tissue factor expression but not CD11b upregulation depends on the presence of platelets |
| Q35839059 | Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system |
| Q47761313 | Molecular identification of the cross-reacting epitope on alphaM beta2 integrin I domain recognized by anti-alphaIIb beta3 monoclonal antibody 7E3 and its involvement in leukocyte adherence |
| Q34236658 | Monoclonal antibody therapy |
| Q44346890 | Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization |
| Q36085620 | Newer agents in antiplatelet therapy: a review |
| Q37131840 | Optimal Duration of Coronary Ligation and Reperfusion for Reperfusion Injury Study in a Rat Model |
| Q33768927 | Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction |
| Q34001532 | Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease |
| Q35813673 | Percutaneous coronary intervention in diabetics |
| Q38547727 | Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future |
| Q34282877 | Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors |
| Q58173541 | Platelet glycoprotein IIb/IIIa receptor inhibition in primary angioplasty for acute myocardial infarction: The new paradigm of direct revascularization |
| Q53249126 | Platelet-monocyte cross talk and tissue factor expression in stable angina vs. unstable angina/non ST-elevation myocardial infarction. |
| Q33862443 | Platelets and restenosis |
| Q28572010 | Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation |
| Q34061211 | Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications |
| Q37709401 | Predictive value of C-reactive protein after drug-eluting stent implantation |
| Q36679440 | Rationale for intracoronary administration of abciximab |
| Q34074021 | Redefining medical treatment in the management of unstable angina |
| Q38622747 | Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution |
| Q45021856 | Rhodostomin, a disintegrin, inhibits adhesion of neutrophils to fibrinogen and attenuates superoxide production |
| Q33417854 | Targeting integrin and integrin signaling in treating thrombosis |
| Q40690209 | The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2). |
| Q35584004 | The Role of Glycoprotein IIb/IIIa-Receptor Antagonists in Diabetics |
| Q35751058 | The beta-tail domain (betaTD) regulates physiologic ligand binding to integrin CD11b/CD18 |
| Q35936923 | The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease |
| Q34675284 | The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors |
| Q64984430 | Tirofiban, a Glycoprotein IIb/IIIa Antagonist, Has a Protective Effect on Decompression Sickness in Rats: Is the Crosstalk Between Platelet and Leukocytes Essential? |
| Q33754183 | Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: applicability to the practice of medicine in the United States |
| Q36255960 | Two functional states of the CD11b A-domain: correlations with key features of two Mn2+-complexed crystal structures |
| Q73538114 | [The efficacy of platelet IIb/IIIa receptor blockers in acute coronary syndromes] |
| Q40904514 | beta-Adrenergic agonist modulation of monocyte adhesion to airway epithelial cells in vitro |
Search more.